Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer

Primary Efficacy Objective: • To evaluate the efficacy of immunotherapy-based treatment combinations in all arms during Stage 1 Secondary Efficacy Objectives: • To evaluate the efficacy of immunotherapy-based treatment combinations in all arms during Stage 1

Atezolizumab, PEGPH20, BL-8040, Cotellic, Trajenta, Tiragolumab

Atezolizumab
BL-8040
Cobimetinib
linagliptin
PEGPH20
Tiragolumab

Injection
Injection
Injection
Injection
Film-coated tablet
Film-coated tablet

600 mg
1200
0.3 mg
73
20
5

Primary Outcome Measures :
Percentage of Participants With Objective Response, as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) [ Time Frame: From Randomization until disease progression or loss of clinical benefit (up to approximately 3-6 years) ]
Percentage of Participants with Adverse Events (AEs) [ Time Frame: From first study treatment administration until 30 days after the last dose or until initiation of new systemic anti-cancer therapy, whichever occurs first (up to approximately 3-6 years) ]
For Arm 1L-A : Percentage of Participants with Serious and Non-serious Treatment-related AEs [ Time Frame: During the safety run-in phase up to 28 days ]

Secondary Outcome Measures :
Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1 [ Time Frame: From randomization up to the first occurrence of disease (up to approximately 3-6 years) ]
Overall Survival (OS) [ Time Frame: From randomization up to death from any cause (up to approximately 3-6 years) ]
Percentage of Participants Who Are Alive at Month 6 and at Month 12 [ Time Frame: Month 6, Month 12 ]
Duration of Response, as Determined by Investigator According to RECIST v1.1 [ Time Frame: From the date of first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 3-6 years) ]
Percentage of Participants With Disease Control, as Determined by the Investigator per RECIST v1.1 [ Time Frame: From randomization until disease progression or loss of clinical benefit (up to approximately 3-6 years) ]
Serum Concentration of Atezolizumab [ Time Frame: Pre-infusion (0 hour [hr]), 30 minutes (min) post-infusion (infusion=60 min) on Day 1 of Cycle 1; pre-infusion (0 hr) on Day 1 of Cycles 2, 3, 4, 8, 12, 16 (each cycle=28 days); 30 days and 120 days after last dose (up to approximately 3-6 years) ]
Plasma Concentration of Cobimetinib [ Time Frame: Prior to cobimetinib dose, 2-4 hr after cobimetinib dose on Day 15 of Cycle 1 (cycle length=28 days) ]
Plasma Concentration of PEGPH20 [ Time Frame: Pre-infusion (0 hr) on Day 1 of Cycle 1 up to 30 days and 120 days after last dose (up to approximately 3-6 years) (Detailed timeframe is provided in outcome measure description) ]
Pre-infusion (0 hr), 5 min and 1-3 hrs post infusion (infusion duration=10-12 min) on Day 1 of Cycle 1; pre-infusion (0 hr) on Days 8 and 15 of Cycle 1, Day 1 of Cycles 3, 4, 8, 12, 16; pre-infusion (0 hr) and 5 min post-infusion on Day 1 of Cycle 2 (each cycle=21 days); 30 days and 120 days after last dose (up to approximately 3-6 years)

Plasma Concentration of BL-8040 [ Time Frame: Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Day 1 of Cycle 1) up to 30 days after last dose (up to approximately 3-6 years) (Detailed timeframe is provided in outcome measure description) ]
Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Day 1 of Cycle 1); 1 hr post-dose on Days 1, 5 of priming period; pre-dose (0 hr), 1 hour post-dose on Day 15 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 8, 12, 16; pre-dose (0 hr) on Day 1 of Cycle 20 and every 4 cycles thereafter (each cycle=21 days) (up to approximately 3-6 years); 30 days after last dose (up to approximately 3-6 years)

Plasma Concentration of Linagliptin [ Time Frame: 2 hr postdose oral linagliptin on Day 1 of Cycle 1, prior to atezolizumab infusion and predose oral linagliptin on Day 15 of Cycle 1 as well as on Day 1 of Cycles 2, 3, and 4 ]
Percentage of Participants With Anti-Drug Antibody (ADA) to Atezolizumab [ Time Frame: Pre-infusion (0 hr) on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 (each cycle=28 days); 30 days and 120 days after last dose (up to approximately 3-6 years) ]
Percentage of Participants With ADA to PEGPH20 [ Time Frame: Pre-infusion (0 hr) on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 (each cycle=21 days); 30 days and 120 days after last dose (up to approximately 3-6 years) ]
Percentage of Participants With ADA to BL-8040 [ Time Frame: Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Day 1 of Cycle 1) up to 30 days after last dose (up to approximately 3-6 years) (Detailed timeframe is provided in outcome measure description) ]
Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Cycle 1 Day 1), Day 15 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 8, 12, 16, 20 and every 4 cycles thereafter (each cycle=21 days) (up to approximately 3-6 years); 30 days after last dose (up to approximately 3-6 years)

Percentage of Participants With Objective Response, in Participants with TIGIT-Positive Tumors by IHC (Esophageal Cancer Cohort Only) [ Time Frame: From Randomization until disease progression or loss of clinical benefit (up to approximately 2 years) ]
Percentage of Participants With Objective Response, in Participants With PD-L1 IC/TC-Positive Tumors by IHC (Esophageal Cancer Cohort Only) [ Time Frame: From Randomization until disease progression or loss of clinical benefit (up to approximately 2 years) ]

Inclusion Criteria
Patients must meet all of the criteria outlined in Sections 1 and 2 below to qualify for Stage 1.
Patients must meet all of the criteria outlined in Sections 2 and 3 below to qualify for Stage 2.
Section 1: Inclusion Criteria for Stage 1
Patients must meet all of the following criteria to qualify for Stage 1:
• Age ≥ 18 years
• ECOG Performance Status of 0 or 1
• Life expectancy ≥ 3 months, as determined by the investigator
• Histologically or cytologically confirmed locally advanced unresectable or metastatic
adenocarcinoma of gastric or gastroesophageal junction
– For patients in the 1L Cohort: no prior systemic therapy for the locally advanced or
metastatic disease
Patients who experience disease progression more than 6 months after the last dose of
adjuvant and/or neoadjuvant therapy are eligible for the 1L Cohort.
– For patients in the 2L Cohort: disease progression during or following a first-line
platinum-containing or fluoropyrimidine-containing chemotherapy regimen
Patients whose disease progresses or recurs within ≤ 6 months after completion of their
adjuvant or neoadjuvant therapy may be allowed to participate in the 2L Cohort, provided
their neo-adjuvant or adjuvant regimen included a combination of at least a platinum
(e.g., cisplatin, carboplatin, or oxaliplatin) and a fluoropyrimidine (e.g., 5-FU, capecitabine,
or S-1). In these cases, the adjuvant or neoadjuvant therapy will count as one prior
(first-line) therapy for gastric cancer.
• Availability of a representative tumor specimen that is suitable for determination of
programmed death−ligand 1 (PD-L1) and/or additional biomarker status by means of
central testing
Baseline tumor tissue samples will be collected from all patients, preferably by means of
a biopsy performed at study entry. If a biopsy is not deemed feasible by the investigator,
archival tumor tissue may be submitted after Medical Monitor approval, provided that the
tissue was obtained from a biopsy performed within 6 months prior to enrollment and
that the patient has not received any anti-cancer therapy since the time of the biopsy.
A formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block
(preferred) or at least 16 slides containing unstained, freshly cut, serial sections must be
submitted along with an associated pathology report prior to study enrollment. If only
10−15 slides are available, the patient may still be eligible for the study, after
Medical Monitor approval.
• Only for the 1L Cohort: patients whose tumors are without HER2 amplification documented
by fluorescence in situ hybridization (FISH) or in situ hybridization (ISH) or are negative by
immunohistochemistry (IHC) 0 or + 1 on previously collected and assessed tumor tissue
upon initial diagnosis of disease by local laboratory testing
If more than one test result from local testing is available, and not all results meet the
inclusion criterion definition, all results should be discussed with the Medical Monitor to
establish eligibility of the patient.
HER2 negativity will be retrospectively confirmed by central laboratory testing
after enrollment. HER2-negative status will be determined on the basis of archival or, if
not available, prescreening biopsy material and defined as:
– FISH or ISH non-amplified (ratio of HER2 to CEP17 < 2.0 or single probe average
HER2 gene copy number <4 signals/cell), or
– IHC 0 or IHC 1+
Section 2: Inclusion Criteria for Stages 1 and 2
Patients must meet all of the following criteria to qualify for Stages 1 and 2:
• Signed Informed Consent Form
• Ability to comply with the study protocol, in the investigator’s judgment
• Measurable disease (at least one target lesion) according to RECIST v1.1
Previously irradiated lesions can be considered as measurable disease only
if progressive disease has been unequivocally documented at that site since radiation.
• Adequate hematologic and end organ function, defined by the following laboratory results
obtained within 14 days prior to initiation of study treatment:
– ANC ≥ 1.5 × 109
/L (1500/µL) without granulocyte colony-stimulating factor support
– WBC count ≥ 2.5 × 109
/L (2500/µL)
– Lymphocyte count ≥ 0.5 × 109
/L (500/µL)
– Platelet count ≥ 100 × 109
/L (100,000/µL) without transfusion
– Hemoglobin ≥ 90.0 g/L (9.0 g/dL)
Patients may be transfused to meet this criterion.
– AST, ALT, and alkaline phosphatase (ALP) ≤ 2.5 × upper limit of normal (ULN) with the
following exceptions:
Patients with documented liver metastases: AST and/or ALT ≤ 5 × ULN
Patients with documented liver or bone metastases: ALP ≤ 5 × ULN
– Serum bilirubin ≤ 1.5 × ULN, with the following exception:
Patients with known Gilbert disease: serum bilirubin level ≤ 3 × ULN
– Serum albumin ≥ 25 g/L (2.5 g/dL)
– Creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 30 mL/min (calculated using the
Cockcroft-Gault formula)
– For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 × ULN
– For patients receiving therapeutic anticoagulation: stable anticoagulant regimen
• Tumor accessible for biopsy
If a biopsy is not deemed feasible by the investigator, archival tumor tissue may be
submitted after Medical Monitor approval, provided that the tissue was obtained from a
biopsy performed within 6 months prior to enrollment and that the patient has not
received any anti-cancer therapy since the time of the biopsy
• For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive measures as outlined for each specific
treatment arm
• For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive measures, and agreement to refrain from donating sperm, as outlined for
each specific treatment arm
Section 3: Inclusion Criteria for Stage 2
Patients must meet all of the following criteria to qualify for Stage 2:
• ECOG Performance Status of 0−2
• Patients in a control arm during Stage 1: ability to initiate Stage 2 treatment within
3 months after experiencing unacceptable toxicity, provided that Medical Monitor approval
for entry into Stage 2 is obtained, or disease progression per RECIST v1.1 while receiving
treatment
• Patients in an experimental arm during Stage 1: ability to initiate Stage 2 treatment within
3 months after experiencing unacceptable toxicity not related to atezolizumab, provided that
Medical Monitor approval for entry into Stage 2 is obtained, or loss of clinical benefit as
determined by the investigator (see Section 3.1.1 for details) while receiving treatment
• Availability of a tumor specimen from a biopsy performed upon discontinuation of Stage 1
(if deemed clinically feasible by the investigator) because of unacceptable toxicity, disease
progression per RECIST v1.1, or loss of clinical benefit as determined by the investigator

Exclusion Criteria
There are specific exclusion criteria for both cohorts and all the arms. Patients will be excluded
from enrollment in Stage 1 or Stage 2 if they meet any of the following criteria outlined in
subsequent sections, as summarized by treatment arm in the table below. If a patient is eligible
only for a control arm, the patient will not be enrolled in the study.
Section 1: Exclusion Criteria for 2L Cohort, Stage 1
Patients who meet any of the following criteria will be excluded from the 2L Cohort, Stage 1:
• Urinary protein is > 1 + on dipstick and the required following 24-hour urine collection shows
urinary protein > 2000 mg (24-hour urine collection is required only if urinary protein is > 1 +
on dipstick)
• Serious or non-healing wound, peptic ulcer, or bone fracture within 28 days prior to initiation
of study treatment
• History of gastrointestinal perforation and/or fistulae within 6 months prior to initiation of
study treatment
• Presence of a bowel obstruction, history or presence of inflammatory enteropathy, or
extensive intestinal resection (e.g., hemicolectomy or extensive small intestine resection
with chronic diarrhea), Crohn disease, ulcerative colitis, or chronic diarrhea
• Uncontrolled arterial hypertension ≥ 150/ ≥ 90 mmHg despite standard medical management
• Chronic therapy with non-steroidal anti-inflammatory agents (non-steroidal
anti-inflammatory drugs [NSAIDs], e.g., indomethacin, ibuprofen, naproxen or similar agents)
or other anti-platelet agents (e.g., clopidogrel, ticlopidine, dipyridamole, anagrelide, or
similar agents)
Aspirin use at doses of up to 325 mg/day is permitted.
Section 2: Exclusion Criteria for Stage 1
Patients who meet any of the following criteria will be excluded from Stage 1:
• Systemic treatment for gastric cancer within 2 weeks or 5 half-lives of the drug (whichever
is longer) prior to initiation of study treatment
• Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies,
including anti−CTLA-4, anti−PD-1, and anti−PD-L1 therapeutic antibodies
• Treatment with investigational therapy within 28 days prior to initiation of study treatment
• Patients with Type 2 diabetes mellitus currently under treatment with DPP-4 inhibitors
• Known dihydropyrimidine dehydrogenase deficiency
Section 3: Exclusion Criteria for Stages 1 and 2
Patients who meet any of the following criteria will be excluded from Stage 1 and from Stage 2:
• Prior treatment with any of the protocol-specified study treatments, with the exception of
chemotherapy, radiotherapy, and atezolizumab given in Stage 1
• Patients with a signet ring cells dominant carcinoma (> 50% of the tumor)
• Weight loss > 5% within 4 weeks prior to screening
• Uncontrolled pleural effusion, pericardial effusion, or ascites
Use of an indwelling catheter (e.g., PleurX®
) is allowed.
• Uncontrolled tumor-related pain
Patients requiring narcotic pain medication must be on a stable regimen at study entry.
Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement)
amenable to palliative radiotherapy should be treated prior to initiation of study treatment.
Patients should be recovered from the effects of radiation. There is no required minimum
recovery period.
Asymptomatic metastatic lesions that would likely cause functional deficits or intractable
pain with further growth (e.g., epidural metastasis that is not presently associated with
spinal cord compression) should be considered for loco-regional therapy if appropriate
prior to the initiation of study treatment
• Uncontrolled hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or
corrected serum calcium greater than the ULN) or symptomatic hypercalcemia requiring
continued use of bisphosphonate therapy
Patients who are receiving bisphosphonate therapy for other reasons (e.g., bone
metastases or osteoporosis) and who do not have a history of clinically significant
hypercalcemia are eligible for the study.
• Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
Patients with a history of treated CNS metastases are eligible, provided that all of the
following criteria are met:
– Measurable disease, per RECIST v1.1, must be present outside the CNS.
– The patient has no history of intracranial hemorrhage or spinal cord hemorrhage.
– Metastases are limited to the cerebellum or the supratentorial region (i.e., no
metastases to the midbrain, pons, medulla, or spinal cord).
– There is no evidence of interim progression between completion of CNS-directed
therapy and the screening brain scan.
– The patient has not received stereotactic radiotherapy within 7 days prior to initiation
of study treatment or whole-brain radiotherapy within 14 days prior to initiation of
study treatment.
– The patient has no ongoing requirement for corticosteroids as therapy for CNS
disease. Anti-convulsant therapy at a stable dose is permitted.
– Asymptomatic patients with CNS metastases newly detected at screening are eligible
for the study after receiving radiotherapy or surgery, with no need to repeat the
screening brain scan.
• History of leptomeningeal disease
• Active or history of autoimmune disease or immune deficiency, including, but not limited to,
myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus,
rheumatoid arthritis, inflammatory bowel disease, anti−phospholipid antibody syndrome,
Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis,
with the following exceptions:
Patients with a history of autoimmune-related hypothyroidism who are on
thyroid-replacement hormone are eligible for the study.
Patients with controlled Type 1 diabetes mellitus who are on a stable insulin regimen are
eligible for the study.
Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic
manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the
study provided all of following conditions are met:
– Rash must cover < 10% of body surface area
– Disease is well controlled at baseline and requires only low-potency
topical corticosteroids
– No occurrence of acute exacerbations of the underlying condition requiring psoralen
plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin
inhibitors, or high-potency or oral corticosteroids within the previous 12 months
• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans),
drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on
screening chest computed tomography (CT) scan
History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
• Positive test for HIV at screening
Patients without a prior positive HIV test result will undergo an HIV test at screening,
unless not permitted per local regulations.
• Active hepatitis B virus (HBV) infection, defined as having a positive hepatitis B surface
antigen (HBsAg) test at screening
Patients with a past or resolved HBV infection (chronic or acute), defined as having a
negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test at
screening are eligible for the study if HBV DNA is negative or undetectable.
• Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test
followed by a positive HCV RNA test at screening
The HCV RNA test will be performed only for patients who have a positive
HCV antibody test.
• Known clinically significant liver disease, including alcoholic hepatitis, cirrhosis, fatty liver
disease, and inherited liver disease
• Active tuberculosis
• Severe infection within 4 weeks prior to initiation of study treatment, including, but not
limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
• Treatment with therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to
initiation of study treatment
Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or
chronic obstructive pulmonary disease exacerbation) are eligible for the study.
• Significant cardiovascular disease (such as New York Heart Association Class II or greater
cardiac disease, myocardial infarction, carotid artery disease requiring intervention or
treatment, or cerebrovascular accident) within 12 months prior to initiation of study
treatment, or unstable arrhythmia or unstable angina within 3 months prior to initiation of
study treatment
• Significant bleeding disorder, vasculitis, Grade ≥ 3 hemorrhage, or significant bleeding
episode from a gastrointestinal tract event within 3 months prior to initiation of
study treatment
• History of deep vein thrombosis, pulmonary embolism, or any other significant
thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are
not considered “significant”) within 3 months prior to initiation of study treatment
• Prior allogeneic stem cell or solid organ transplantation
• Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of
study treatment, or anticipation of need for a major surgical procedure during the study
Placement of central venous access catheter (e.g., port or similar) is not considered a
major surgical procedure and is therefore permitted.
• Treatment with anticoagulation with warfarin, low-molecular-weight heparin, or similar
agents for therapeutic purposes
Patients receiving prophylactic, low-dose anticoagulation therapy are eligible provided
that the coagulation parameters defined in the inclusion criteria are met.
• History of malignancy other than gastric or gastroesophageal junction carcinoma within
2 years prior to screening, with the exception of those with a negligible risk of metastasis or
death (e.g., expected 5-year overall survival [OS] > 90%), such as adequately treated
carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer,
ductal carcinoma in situ, or Stage I uterine cancer
• Any other diseases, metabolic dysfunction, physical examination finding, or clinical
laboratory finding that contraindicates the use of an investigational drug, may affect the
interpretation of the results or may render the patient at high risk from treatment
complications
• Pregnancy or breastfeeding or intention of becoming pregnant during the study
Women of childbearing potential must have a negative serum pregnancy test within
14 days prior to the first study treatment administration.
• Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment,
or anticipation of need for such a vaccine during treatment with atezolizumab, and for
5 months after the last dose of atezolizumab
• History of severe allergic, anaphylactic reactions to chimeric or humanized antibodies or
fusion proteins
• Known hypersensitivity to Chinese hamster ovary cell products or recombinant
human antibodies
• Known allergy or hypersensitivity to any of the study drugs or their excipients
• Known dihydropyrimidine dehydrogenase deficiency or thymidylate synthase gene
polymorphism predisposing the patient to 5-FU toxicity
• Treatment with systemic immunostimulatory medication (including, but not limited to,
interferon and interleukin-2) within 4 weeks or 5 half-lives of the drug (whichever is longer)
prior to the initiation of study treatment
• Treatment with systemic immunosuppressive medication (including, but not limited to,
corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti−tumor
necrosis factor−α [anti−TNF-α] agents) within 2 weeks prior to initiation of study treatment,
or anticipation of the need for systemic immunosuppressant medication during the study,
with the following exceptions:
– Patients who received acute, low-dose, systemic immunosuppressant medications or a
one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of
corticosteroids for a contrast allergy) are eligible for the study after Medical Monitor
approval has been obtained.
– Patients who received mineralocorticosteroids (e.g., fludrocortisone), corticosteroids for
chronic obstructive pulmonary disease or asthma, or low-dose corticosteroids for
orthostatic hypotension or adrenal insufficiency are eligible for the study.
• Requirement for use of denosumab during the study
Patients who are receiving denosumab for any reason (including hypercalcemia) must
be willing and eligible to receive a bisphosphonate instead while in the study.
• Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1 or better,
with the exception of alopecia of any grade and Grade ≤ 2 peripheral neuropathy
Section 4: Exclusion Criteria for Arms Containing Cobimetinib during Stages 1 and 2
Patients who meet any of the following criteria will be excluded from the Atezo + Cobi arm or
from the mFOLFOX6 +Atezo + Cobi arm during Stages 1 and 2:
• Prior treatment with MAPK inhibitors (including cobimetinib)
• Inability to swallow medication or malabsorption condition that would alter the absorption of
orally administered medications
• Inability to tolerate atezolizumab during Stage 1
• Left ventricular ejection fraction below institutional lower limit of normal or below 50%,
whichever is lower
• History of or evidence of retinal pathology on ophthalmologic examination that is considered
a risk factor for neurosensory retinal detachment, central serous chorioretinopathy, retinal
vein occlusion (RVO), or neovascular macular degeneration
Patients will be excluded from study participation if they currently are known to have any
of the following risk factors for RVO:
– History of serous retinopathy
– History of retinal RVO
– Evidence of ongoing serous retinopathy or RVO at baseline
Section 5: Exclusion Criteria for Atezo + PEGPH20 Arm during Stage 1
Patients who meet any of the following criteria will be excluded from the Atezo +PEGPH20 arm
during Stage 1:
• Treatment with megestrol acetate within 10 days prior to initiation of study treatment
• Contraindication to heparin as per institutional guidelines